Literature DB >> 34369869

Autoimmune disorders of platelet function: systematic review of cases of acquired Glanzmann thrombasthenia and acquired delta storage pool disease.

Monica Bacci1, Antonietta Ferretti2, Marina Marchetti3, Maria A Alberelli2, Anna Falanga3,4, Corrado Lodigiani1,5, Erica De Candia1,6.   

Abstract

Acquired platelet function disorders (PFD) are rare bleeding diseases that should be suspected in all patients with unexplained mucocutaneous bleedings of recent onset, with no previous history of haemorrhages, and with normal coagulation test and platelet count. Drug-induced platelet function bleeding disorders are the most frequent PFDs and can easily be identified on the basis of recent administration of platelet-inhibiting drugs. Apart from these, the most challenging acquired PFDs are those caused by autoimmune mechanisms. In fact, demonstration of autoantibodies inhibiting platelet function may be difficult in most non-specialised centres. Among autoimmune PFDs (aPFDs), acquired Glanzmann thrombasthenia (aGT), which is caused by autoantibodies that bind to platelet αIIbβ3 integrin, inhibiting its function, is the most frequent. aGT can be associated with underlying haematological malignancies or autoimmune diseases but can also be idiopathic. More rarely, other immune-mediated PFDs can occur, such as acquired delta storage pool disease (aδSPD). Treatment of aPFDs must rely on the control of acute and chronic bleedings, treatment of the underlying disease in secondary forms, and immunosuppressive treatment for autoantibody reduction or eradication. aPFDs may completely resolve upon treatment of any underlying disease that may be present. In primary aPFDs, and in the majority of secondary forms, treatment relies on immunosuppressive therapies.Here we present a systematic review of previously described immune-mediated aGT and aδSPD cases. Clinical and laboratory characteristics, treatments for the control of bleedings and for the eradication of autoantibodies, and responses to treatments are also discussed. Although no guidelines are available for the management of these very rare conditions, presentation of all cases reported so far can help clinicians in the diagnosis and treatment of these life-threatening diseases.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34369869      PMCID: PMC9480966          DOI: 10.2450/2021.0119-21

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   5.752


  49 in total

Review 1.  Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder.

Authors:  Eleni Tholouli; Charles R M Hay; Peter O'Gorman; Michael Makris
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

2.  Acquired Glanzmann's thrombasthenia variant and immune thrombocytopenia in a renal transplant recipient receiving tacrolimus.

Authors:  Christian Morath; Till Hoffmann; Elisabeth M Kirchhoff; Jeanne Sis; Martin Zeier; Rüdiger E Scharf; Konrad Andrassy
Journal:  Thromb Haemost       Date:  2005-10       Impact factor: 5.249

3.  [Pseudo-Glanzmann thrombasthenia in the course of autoimmune thrombocytopenic purpura].

Authors:  B Granel; L Swiader; V Veit; J Rey; D Reviron; P Disdier; J R Harlé; P J Weiller
Journal:  Rev Med Interne       Date:  1998-11       Impact factor: 0.728

4.  Successful use of recombinant factor VIIa in a patient with acquired Glanzmann thrombasthenia.

Authors:  M Tuffigo; E Lazaro; C James; C Subtil; J-F Viallard; M Fiore
Journal:  Haemophilia       Date:  2014-12-04       Impact factor: 4.287

5.  Acquired "storage pool disease" of platelets associated with circulating antiplatelet antibodies.

Authors:  J Zahavi; V J Marder
Journal:  Am J Med       Date:  1974-06       Impact factor: 4.965

6.  Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.

Authors:  Maria Adele Alberelli; Idanna Innocenti; Francesco Autore; Luca Laurenti; Erica De Candia
Journal:  Haematologica       Date:  2017-12-14       Impact factor: 9.941

7.  Acquired thrombasthenia due to GPIIb/IIIa-specific platelet autoantibodies.

Authors:  H Niessner; K J Clemetson; S Panzer; C Mueller-Eckhardt; S Santoso; P Bettelheim
Journal:  Blood       Date:  1986-08       Impact factor: 22.113

8.  Severe platelet dysfunction in hairy cell leukemia with improvement after splenectomy.

Authors:  M H Rosove; F Naeim; S Harwig; J Zighelboim
Journal:  Blood       Date:  1980-06       Impact factor: 22.113

9.  Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies.

Authors:  Dorit Blickstein; Rima Dardik; Esther Rosenthal; Judith Lahav; Yair Molad; Aida Inbal
Journal:  Isr Med Assoc J       Date:  2014-05       Impact factor: 0.892

10.  Combination of acquired von Willebrand syndrome (AVWS) and Glanzmann thrombasthenia in monoclonal gammopathy of uncertain significance (MGUS), a case report.

Authors:  Elizabeth Sarah Mayne; Malcolm Tait; Barry Frank Jacobson; Evashin Pillay; Susan J Louw
Journal:  Thromb J       Date:  2018-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.